Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Clinical research in female hormones and thrombosis. Clinical trial using recombinant antithrombin (AT)in patients with hereditary AT deficiency Retrospective study to identify clinical/laboratory risk factors for vascular thrombosis in patients with factor V Leiden and Prothrombin G20210A mutations.

Highlights

  1. 1
    Thrombosis research · 2021
    MTMaria Teresa DeSancho
    PMID: 33517168DOIFirst author3 citations
  2. 2
    Journal of thrombosis and thrombolysis · 2023
    MTMaria Teresa DeSancho
    PMID: 36967425DOISenior author10 citations
  3. 3
    Journal of thrombosis and thrombolysis · 2022
    MPMartin PrinceDMDaniel MargolisMTMaria Teresa DeSancho
    PMID: 35689139PMCID: PMC9186283DOISenior author7 citations

Publications

85 publications

Funding

6 grants

Active

2 grants
  • Sub-PI
    University of Pittsburgh - Weill Cornell Services Agreement - PRESENCE Study
    National Heart, Lung, and Blood Institute · 2025–2028 · via University of Pittsburgh
    No publications yet
    UH3HL165839-02S1
  • MPI
    Immune Tolerance Network
    National Institute of Allergy and Infectious Diseases · 2024–2028 · via Benaroya Research Institute at Virginia Mason
    UM1AI109565-13
Completed grants (4)
  • PI
    ATHNdataset Hereditary Antithrombin Deficiency (HAD) Pilot Project
    American Thrombosis & Hemostasis Network, Inc. · 2020–2024Contract
    SA 201403-01
  • PI
    Hereditary Antithrombin Deficiency and Pregnancy
    American Society of Hematology Inc · 2023–2024
    ASH 234822-01
  • Sub-PI
    ATHN 17: Monitoring of venous thromboembolisms among non-hospitalized COVID-19 survivors
    Centers for Disease Control and Prevention · 2023–2023 · via American Thrombosis & Hemostasis Network, Inc.
    No publications yet
    NU38OT000280-04-02
  • KP
    Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
    National Heart, Lung, and Blood Institute · 2011–2016 · via Washington University, The
    U01HL088476-03EWO

Clinical research

13 studies

Active

4 studies
  • PI
    Repository of clinical, laboratory and radiologic data of patients exposed to anticoagulant therapy
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
  • PI
    Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain: Promoting Engagement in Cognitive Behavioral Therapy
    NA · University of Pittsburgh · OPEN TO ACCRUAL (as of 2025)
    Pain; Sickle Cell Disease
    NCT06374238
  • PI
    A Multicenter, Prospective, Open-label, Uncontrolled Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
    PHASE3 · Octapharma USA, Inc · OPEN TO ACCRUAL (as of 2025)
    Congenital Antithrombin Deficiency
    NCT04918173
  • PI
    Targeting CD38 With Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial (ITN093AI)
    PHASE1; PHASE2 · Immune Tolerance Network · OPEN TO ACCRUAL (as of 2024)
    Autoimmune Disorders
    NCT05671757
Completed & closed trials (9)
  • PI
    A Phase 2b, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of TAK-755 (rADAMTS13) With Minimal to No Plasma Exchange (PEX) in the Treatment of Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
    PHASE2 · Takeda Development Center Americas, Inc. · IRB STUDY CLOSURE (as of 2026)
    Thrombotic Thrombocytopenic Purpura (TTP)
    NCT05714969
  • PI
    A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE
    PHASE3 · Anthos Therapeutics · CLOSED TO ACCRUAL (as of 2025)
    Venous Thromboembolism; Deep Venous Thrombosis; Pulmonary Embolism
    NCT05171075
  • PI
    Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)
    PHASE1; PHASE2 · Alpine Immune Sciences, Inc. · CLOSED TO ACCRUAL (as of 2025)
    Idiopathic Thrombocytopenic Purpura; Immune Thrombocytopenia; Warm Autoimmune Hemolytic Anemia; Cold Agglutinin Disease
    NCT05757570
  • PI
    Cold Agglutinin Disease Real World Evidence Registry
    Sanofi S.A. · CLOSED TO ACCRUAL (as of 2025)
  • PI
    A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
    PHASE3 · Swedish Orphan Biovitrum AB · IRB STUDY CLOSURE (as of 2024)
    Cold Agglutinin Disease
    NCT05096403
  • PI
    A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Subjects With Sickle Cell Disease
    PHASE1 · Agios Pharmaceuticals, Inc. · IRB STUDY CLOSURE (as of 2024)
    Healthy Volunteers; Anemia, Sickle Cell
    NCT04536792
  • PI
    A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
    PHASE2 · Incyte, Inc. · IRB STUDY CLOSURE (as of 2024)
    Autoimmune Hemolytic Anemia
    NCT03538041
  • PI
    InterMediate ProphylACtic Versus Therapeutic Dose Anticoagulation in Critically Ill Patients With COVID-19: A Prospective Randomized Study (The IMPACT Trial)
    PHASE4 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2023)
    COVID-19
    NCT04406389
  • PI
    Emergency Use of Hemopure in Patient B-M
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)

Mentoring

2 menteesAll publications with mentees →